NPS Pharmaceuticals to Present at Leerink Swann Hot Topics in Therapeutics Roundtable Conference

BEDMINSTER, N.J.--(BUSINESS WIRE)-- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference in New York on Thursday, February 17, 2011 at 2:20 p.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/events.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is in Phase 3 development for parenteral nutrition dependent adult short bowel syndrome and is in preclinical development for additional intestinal failure related conditions. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 3 development as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at http://www.npsp.com.



CONTACT:

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335

KEYWORDS:   United States  North America  Canada  New Jersey

INDUSTRY KEYWORDS:   Health  Clinical Trials  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.